BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 9739932)

  • 21. [Mononucleosis syndrome with viro-immunologic parameters similar to those of a primary HIV-1 infection after interruption of highly effective anti-retroviral treatment].
    Orbea Ríos L; Domínguez Castellanos A; Justo Alpañés E
    An Med Interna; 2002 Jun; 19(6):321-2. PubMed ID: 12152394
    [No Abstract]   [Full Text] [Related]  

  • 22. Nipping HIV in the bud.
    Smart T
    GMHC Treat Issues; 1996 Aug; 10(8):3-6. PubMed ID: 11363719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Which is the strategy? The latest in the use of antiretrovirals].
    Agosto M
    Sidahora; 1995; ():33-4. PubMed ID: 11363205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA triple header. Food and Drug Administration.
    Smart T
    GMHC Treat Issues; 1995 Nov; 9(11):1-3. PubMed ID: 11362986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
    Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
    J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protease inhibitors and prevention of cross resistance.
    Levin J
    AIDS Treat News; 1995 Oct; (no 232):1-3. PubMed ID: 11362875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The choice of HIV protease inhibitor: indinavir is currently the best option.
    Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection.
    Smith D; Berrey MM; Robertson M; Mehrotra D; Markowitz M; Perrin L; Clumeck N; Lazzarin A; Burckhardt B; Weber R; Corey L; Cooper DA
    J Infect Dis; 2000 Sep; 182(3):950-4. PubMed ID: 10950796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiretrovirals.
    Temesgen Z; Wright AJ
    Mayo Clin Proc; 1999 Dec; 74(12):1284-301. PubMed ID: 10593358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New developments in antiretroviral drug therapy for HIV-1 infections.
    Johnson VA
    AIDS Clin Rev; 1995-1996; ():305-46. PubMed ID: 7488558
    [No Abstract]   [Full Text] [Related]  

  • 32. Saquinavir therapy in patients with the advanced HIV infection and liver cirrhosis.
    Tachikawa N; Yoshizawa S; Kikuchi Y; Yasuoka A; Oka S
    Jpn J Infect Dis; 1999 Aug; 52(4):177-8. PubMed ID: 10592905
    [No Abstract]   [Full Text] [Related]  

  • 33. Conference looks at HIV drug resistance.
    Chang HE
    GMHC Treat Issues; 1995 Sep; 9(9):6-8. PubMed ID: 11362910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New developments in antiretroviral drug therapy for HIV infection.
    Johnson VA
    AIDS Clin Rev; 1992; ():69-104. PubMed ID: 1318738
    [No Abstract]   [Full Text] [Related]  

  • 35. Study shows three drugs better than two.
    AIDS Alert; 1997 Apr; 12(4):39. PubMed ID: 11364145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [HIV-therapy: as early and as intensive as possible].
    Dtsch Med Wochenschr; 1997 Oct; 122(41):A27. PubMed ID: 9378051
    [No Abstract]   [Full Text] [Related]  

  • 37. Antiretroviral drugs: new agents, new combinations line up against HIV.
    Phillips L
    Hosp Technol Ser; 1996 Jan; 15(1):1-3. PubMed ID: 10161344
    [No Abstract]   [Full Text] [Related]  

  • 38. Protease inhibitors shine in triple combinations.
    AIDS Alert; 1996 Mar; 11(3):31-2. PubMed ID: 11363243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antiretroviral therapy. Current status and perspectives].
    Lüthy R
    Internist (Berl); 1994 Oct; 35(10):896-900. PubMed ID: 8002223
    [No Abstract]   [Full Text] [Related]  

  • 40. Potent new AIDS drugs underscore promise of combination therapy.
    AIDS Alert; 1996 Jan; 11(1):1-4. PubMed ID: 11363225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.